Femme et Homme
- | Pays :
- Spain
- United States
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of the study is to assess the activity of TPI 287 as single agent therapy for patients with advanced, unresectable pancreatic cancer after failure of gemcitabine-containing therapy. Activity of TPI 287 will be determined by the 6-month survival rate.
Critère d'inclusion
- Pancreatic cancer